Bryan Lusk, MD
Ophthalmology · Shreveport, LANPI 1700043643
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,241 of the $9,582 with a category attached, or 65.1%. It is spread thinly across 24 manufacturers, the largest accounting for just 23.6%. Reporting peaked in 2024 at $4,278 and has fallen 85.9% since, to $603 in 2025. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $43.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$2K
- Bausch & Lomb Americas Inc.$2K
- Alcon$1K
- AbbVie$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$413
- Glaukos Corporation$356
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$260%
- Travel & lodging$1,14512%
- Food & beverage$6,24165%
- Education$2,00021%
- Entertainment$1702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 9 | $2,257 |
| Bausch & Lomb Americas Inc. | 14 | $1,744 |
| Alcon | 53 | $1,440 |
| AbbVie(2 entities) | 50 | $1,111 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $413 |
| Glaukos Corporation | 6 | $356 |
| Oyster Point Pharma, Inc. | 8 | $283 |
| Novartis | 12 | $255 |
| Sun Pharmaceutical Industries Inc. | 5 | $236 |
| Mallinckrodt Hospital Products Inc. | 5 | $234 |
| Biotissue Holdings Inc. | 5 | $181 |
| Optos, Inc. | 2 | $170 |
| Kala Pharmaceuticals, Inc. | 9 | $163 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $149 |
| Ivantis, Inc | 2 | $144 |
| Aerie Pharmaceuticals, Inc. | 9 | $143 |
| Sight Sciences, Inc. | 4 | $65 |
| Harrow Eye, LLC | 3 | $59 |
| Tarsus Pharmaceuticals, Inc. | 2 | $48 |
| Thea Pharma Inc. | 2 | $44 |
| Shire North American Group Inc | 2 | $34 |
| Amgen | 1 | $18 |
| Omeros Corporation | 1 | $17 |
| Cardinal Health 200 LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$2,113
- RXSIGHT INJECTOR CARTRIDGE$2,113
- RXSIGHT INJECTOR HANDPIECE$2,113
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$2,113
- LIGHT ADJUSTABLE LENS (LAL)$2,000
- enVista Aspire IOL$1,259
- TENEO$1,259
- STELLARIS ELITE$1,259
- LUMIGAN$250
- AcrySof IQ PanOptix$247
- iDose$157
- LenSx$145
- CEQUA$125
- TYRVAYA$125
- ACTHAR$125
- VYZULTA$125
- COMBIGAN$125
- Hydrus$119
- BIOTRUE$115
- ULTRA$115
How this compares
$9,582 in reported general payments places this provider in the 90th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 70 | $61,513 |
| RestasisCyclosporine | 38 | $56,078 |
| LumiganBimatoprost | 79 | $29,891 |
| ProlensaBromfenac Sodium | 46 | $15,657 |
| TyrvayaVarenicline Tartrate | 22 | $14,051 |
| Fluorometholone | 170 | $14,025 |
| CombiganBrimonidine Tartrate/Timolol | 35 | $10,196 |
| Prednisolone Acetate | 207 | $9,906 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 61 | $8,925 |
| Cyclosporine | 15 | $7,743 |
| Loteprednol Etabonate | 49 | $7,075 |
| RhopressaNetarsudil Mesylate | 16 | $6,936 |
| Brimonidine Tartrate | 131 | $6,756 |
| Ketorolac Tromethamine | 179 | $5,193 |
| Bromfenac Sodium | 15 | $3,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,111 | $96,166152 claims |
| Bausch & Lomb Americas Inc.Xiidra | $1,744 | $61,51370 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $413 | $22,73295 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $283 | $14,05122 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $143 | $6,93616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Shreveport
- Wyche ColemanShreveport$35K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
- Chanping LiangShreveport$15K
- Claude BundrickShreveport$12K
- Arthur KavanaughShreveport$7K
- Ann GuyShreveport$6K
- Jeffrey LuskShreveport$5K
- John CarmodyShreveport$5K
- Blake WilliamsonBaton Rouge$443K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.